Coronary Sinus Isolation for High Burden Atrial Fibrillation. A Randomized Clinical Trial
Date
2024
Authors
Ariyaratnam, J.P.
Middeldorp, M.E.
Brooks, A.G.
Thomas, G.
Kadhim, K.
Mahajan, R.
Pathak, R.K.
Young, G.D.
Kalman, J.M.
Sanders, P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
JACC: Clinical Electrophysiology, 2024; 11(1):1-9
Statement of Responsibility
Jonathan P. Ariyaratnam, Melissa E. Middeldorp, Anthony G. Brooks, Gijo Thomas, Kadhim Kadhim, Rajiv Mahajan, Rajeev K. Pathak, Glenn D. Young, Jonathan M. Kalman, Prashanthan Sanders
Conference Name
Abstract
Background: The coronary sinus is an arrhythmogenic structure that can initiate and maintain atrial fibrillation (AF). Coronary sinus ablation has been shown to be effective in prolonging the AF cycle length and terminating AF in patients with both paroxysmal and persistent AF who have persistent AF after pulmonary vein isolation (PVI). Objectives: The objective of this study was to undertake a randomized controlled trial to investigate the efficacy of coronary sinus isolation (CSI) as an adjunctive ablation strategy for the treatment of high-burden AF. Methods: Consecutive patients presenting with symptomatic long episodes of paroxysmal AF (≥48 h but ≤7 days) or persistent AF (>7 days and ≤12 months) referred for first-time ablation were enrolled. Participants were randomized to either PVI, roofline ablation, and CSI (CSI group) or PVI and roofline ablation only (non-CSI group). Participants were assessed postprocedurally via clinical follow-up and 7-day Holter monitoring at regular intervals. The primary outcome was single-procedure drug-free atrial arrhythmia–free survival at 2 years. Results: A total of 100 participants were recruited to the study; 48 were randomized to the CSI group and 52 to the non-CSI group. Acutely successful CSI was achieved in 45 of the 48 patients in the CSI group. At 2 years follow up, 30 of 48 patients (62.5%) in the CSI group and 33 of 52 (63.4%) in the non-CSI group were free from arrhythmia recurrence. Single-procedure drug-free survival at 2 years was no different between groups (P = 0.91). Similarly, multiple procedure drug assisted survival at 5 years was not different between groups (P = 0.80). Complication rates were not significantly different between groups (P = 0.19). Conclusions: Adjunctive CSI as part of a de novo ablation strategy does not confer any additional benefit greater than PVI and roofline for the treatment of high-burden AF.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2025 the American College of Cardiology Foundation. Published by Elsevier. All rights are reserved, including those for text and data mining, AI training, and similar technologies.